Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Eileen Steiniger

Nurse Practitioner, Gerontology Saint Louis, MO Nurse Practitioner

NPI 1881965515 CMS profile 10766088

4921 Parkview Pl, Div Im Endocrinology Ste 13B, Saint Louis, MO 63110

Open in the dashboard

General payments

$2,447

81 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eileen Steiniger of Saint Louis, MO is reported in the CMS Open Payments database as having received $2,447 across 81 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $530 4
2024 General $640 10
2023 General $328 16
2022 General $483 22
2021 General $466 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eileen Steiniger
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Eileen Steiniger were reported at $530. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Eileen Steiniger Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $466 $133 $44–$396 $132
2022 $483 $142 $48–$452 $149
2023 $328 $158 $53–$482 $160
2024 $640 $171 $55–$533 $164
2025 $530 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lilly USA, LLC $594 17 payments
  2. Novo Nordisk Inc $273 16 payments
  3. Beta Bionics, Inc. $267 2 payments
  4. Medtronic, Inc. $257 2 payments
  5. Amgen Inc. $194 4 payments
  6. Sequel Med Tech, LLC $149 1 payment
  7. Pfizer Inc. $99 5 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $92 5 payments
  9. Abbott Laboratories $65 3 payments
  10. Amarin Pharma Inc. $58 4 payments
  11. Other $398 22 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,447 81 payments
Products named General payments · program years 2021–2025
  1. MOUNJARO $306 6 payments
  2. MINIMED 780G $257 2 payments
  3. Ozempic $209 12 payments
  4. RYBELSUS $184 11 payments
  5. JARDIANCE $173 10 payments
  6. EVENITY $156 2 payments
  7. TWIIST $149 1 payment
  8. iLet Bionic Pancreas Automated insulin delivery system $141 1 payment
  9. iLet Bionic Pancreas Automated insulin delivery system $141 1 payment
  10. iLet Bionic Pancreas Automated insulin delivery system $141 1 payment
  11. Other $1,923 77 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

1,203

Median for Nurse Practitioner: 389

Drug cost

$431,121

Median for Nurse Practitioner: $21,885

Branded share of claims

40.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 122 $140,670
Trulicity Dulaglutide Brand 76 $101,738
Mounjaro Tirzepatide Brand 77 $92,516
Jardiance Empagliflozin Brand 40 $42,581
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 17 $11,765
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 12 $9,562
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 41 $5,373
Baqsimi Glucagon Brand 12 $4,877
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 13 $4,046
Humalog Kwikpen U-100 Insulin Lispro Brand 19 $3,175

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$20,010

Medicare's payments for the services billed

Medicare patients

145

Average age 67

Services billed

540

77 women, 68 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Chronic kidney disease 55%
Arthritis 42%
Ischemic heart disease 37%
Depression 37%
Heart failure 32%
COPD 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $111
$111 77 —
Tymlos
  • Radius Health, Inc. $33
$33 — —
AFREZZA
  • Mannkind Corporation $17
$17 — —
RYBELSUS
  • Novo Nordisk Inc $7
$7 — —
Ozempic
  • Novo Nordisk Inc $7
$7 122 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

81 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Gerontology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record